FDA Adds Three “Qualifying Pathogens” For Potential Antibiotic Incentives
This article was originally published in The Pink Sheet Daily
Final rule includes a total of 21 pathogens, but agency notes a drug intended to treat a pathogen on the list is not guaranteed a QIDP designation for priority review and potential added marketing exclusivity.
You may also be interested in...
The US FDA heard a lot about the structural, medical and especially financial barriers facing coccidioidomycosis, or Valley fever, drug development soon after the agency refused to qualify the rare fungal infection for priority review voucher incentives.
Big pharma is not the prime player in the tropical disease area, even as some large firms increase funding.
Durata has post-marketing requirements to continue resistance-related studies, but its label includes stewardship language similar to other antibiotics.